“We have agreed to double the number of the BioNTech and Pfizer vaccine. This shows that we now have more than sufficient doses, but we should think not just of ourselves but others who need our support” European Commission president Ursula von der Leyen
The Eropean Commission is set to acquire more 200 million doses of the COVID-19 vaccine produced by BioNTech and Pfizer.
Additional 100 million doses, will enable the EU to purchase up to 600 million doses of the vaccine.
The additional 200 million doses comes on top of the 300 million already ordered from BioNTech and Pfizer and will be delivered starting in the Spring.
The Commission has also signed deals with AstraZeneca (400 million doses), Sanofi-GSK (300 million doses), Johnson and Johnson (400 million doses), CureVac (405 million doses) and Moderna (160 million doses).
At a news conference to announce the deal, European Commission president Ursula von der Leyen, said there were now 2.3 billion doses of vaccines on order from six pharmaceutical companies, including BioNTech and Pfizer.
“We have agreed to double the number of the BioNTech and Pfizer vaccine,” She said, adding that this would make it possible to vaccinate Europe’s 450 million population and also those from its near neighbours.
“They also need our support,” she told reporters, adding. “It shows that we now have more than sufficient doses, but we should think not just of ourselves but others who need our support,” she stressed.